References
- Greenberg MS. 2006. Handbook of neurosurgery. 7th ed. New York: Thieme Medical Publishers.
- Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011;4(2):233–242. doi:https://doi.org/10.1586/ecp.11.1.
- Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, et al. Corticosteroids compromise survival in glioblastoma. Brain 2016;139(Pt 5):1458–14571. doi: https://doi.org/10.1093/brain/aww046
- Hockey B, Leslie K, Williams D. Dexamethasone for intracranial neurosurgery and anaesthesia. J Clin Neurosci. 2009;16(11):1389–1393. doi:https://doi.org/10.1016/j.jocn.2009.03.007.
- Sethi R, Naqash IA, Bajwa SS, Dutta V, Ramzan A, Zahoor S, et al. Evaluation of hyperglycaemic response to intra-operative dexamethasone administration in patients undergoing elective intracranial surgery: a randomised, prospective study. Asian J Neurosurg. 2016;11(2):98–102. doi:https://doi.org/10.4103/1793-5482.177660.
- Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. Curr Oncol. 2014;21(3):e493–e503. doi:https://doi.org/10.3747/co.21.1769.
- Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA, et al. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. JCO. 2009;27(7):1082–1086. doi:https://doi.org/10.1200/JCO.2008.19.1098.
- Löwenberg M, Verhaar AP, van den Brink GR, Hommes DW. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med. 2007;13(4):158–163. doi:https://doi.org/10.1016/j.molmed.2007.02.001.
- Cenciarini M, Valentino M, Belia S, Sforna L, Rosa P, Ronchetti S, et al. Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies. Front Mol Neurosci. 2019;12:65. doi:https://doi.org/10.3389/fnmol.2019.00065.
- Das A, Banik NL, Patel SJ, Ray SK. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol Cancer. 2004;3(1):36. doi:https://doi.org/10.1186/1476-4598-3-36.
- Guan Y, Chen J, Zhan Y, Lu H. Effects of dexamethasone on C6 cell proliferation, migration and invasion through the upregulation of AQP1. Oncol Lett. 2018;15(5):7595–7602. doi:https://doi.org/10.3892/ol.2018.8269.
- Liu H, Huang X, Wang H, Shen A, Cheng C. Dexamethasone inhibits proliferation and stimulates SSeCKS expression in C6 rat glioma cell line. Brain Res. 2009;1265:1–12. doi:https://doi.org/10.1016/j.brainres.2009.01.050.
- Gündisch S, Boeckeler E, Behrends U, Amtmann E, Ehrhardt H, Jeremias I, et al. Glucocorticoids augment survival and proliferation of tumor cells. Anticancer Res. 2012;32(10):4251–4261.
- Villeneuve J, Galarneau H, Beaudet M-J, Tremblay P, Chernomoretz A, Vallières L, et al. Reduced glioma growth following dexamethasone or anti-angiopoietin 2 treatment. Brain Pathol. 2008;18(3):401–414. doi:https://doi.org/10.1111/j.1750-3639.2008.00139.x.
- Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res. 2004;10(5):1633–1644. doi:https://doi.org/10.1158/1078-0432.ccr-0829-3.
- Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139(Pt 5):1458–1471. doi:https://doi.org/10.1093/brain/aww046.
- Bauman GS, MacDonald W, Moore E, Ramsey DA, Fisher BJ, Amberger VR, et al. Effects of radiation on a model of malignant glioma invasion. J Neurooncol. 1999;44(3):223–231. doi:https://doi.org/10.1023/a:1006319417077.
- Lin Y-M, Jan H-J, Lee C-C, Tao H-Y, Shih Y-L, Wei H-W, et al. Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism. Eur J Pharmacol. 2008;593(1–3):1–9. doi:https://doi.org/10.1016/j.ejphar.2008.06.111.
- McGranahan T, Therkelsen KE, Ahmad S, Nagpal S. Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol. 2019;20:24. doi:https://doi.org/10.1007/s11864-019-0619-4.
- with glio. Chitadze G, Fluh C, Quabius ES, Freitag-Wolf S, Peters C, Lettau M, et al. In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. Oncoimmunology. 2017;6(11):8. doi: https://doi.org/10.1080/2162402X.2017.1358839.
- Mason M, Maurice C, McNamara MG, Tieu MT, Lwin Z, Millar BA, et al. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. J Neurooncol. 132(3):463-471 (2017). doi: https://doi.org/10.1007/s11060-017-2395-y
- Neuwelt EA, Kikuchi K, Hill S, Lipsky P, Frenkel EP. Immune responses in patients with brain tumors. Factors such as anti-convulsants that may contribute to impaired cell-mediated immunity. PubMed – NCBI. [cited 2019 Jan 1]. https://www.ncbi.nlm.nih.gov/pubmed/6821814.
- Maxwell R, Luksik AS, Garzon-Muvdi T, Hung AL, Kim ES, Wu A, et al. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. [cited 2019 Jan 1]. PubMed – NCBI. https://www.ncbi.nlm.nih.gov/pubmed/30524891.
- Gustafson MP, Lin Y, New KC, Bulur PA, O'Neill BP, Gastineau DA, et al. Systemic immune suppression in glioblastoma: the interplay between CD14 + HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. PubMed – NCBI. [cited 2019 Jan 1]. https://www.ncbi.nlm.nih.gov/pubmed/20179016.
- Read SB, Kulprathipanja NV, Gomez GG, Paul DB, Winston KR, Robbins JM, et al. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modifi…. [cited 2019 Jan 2]. PubMed – NCBI. https://www.ncbi.nlm.nih.gov/pubmed/14511464.
- Takagi Y, Kikuchi T, Niimura M, Ohno T. Effects of glucocorticoids on antitumor effects of immunizations with fusions of dendritic and tumor cells. Anticancer Res. 2019;23(3B):2553-2558. https://www.ncbi.nlm.nih.gov/pubmed/12894540.
- Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg. 2000;93(4):634–9. doi: https://doi.org/10.3171/jns.2000.93.4.0634
- Moyes KW, Davis A, Hoglund V, Haberthur K, Lieberman NA, Kreuser SA, et al. Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma. Oncoimmunology. 2018;7(11):e1507668. doi:https://doi.org/10.1080/2162402X.2018.1507668.
- Wong ET, Lok E, Gautam S, Swanson KD. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer. 2015;113(2):232–241. doi:https://doi.org/10.1038/bjc.2015.238.
- Campian JL, Piotrowski AF, Ye Xiaobu, Hakim FT, Rose J et al. Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide. Obs Study 2017;135(2):343–351. doi:https://doi.org/10.1007/s11060-017-2580-z.
- Ram Z, Walbridge S, Heiss JD, Culver KW, Blaese RM, Oldfield EH. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. . J Neurosurg. 1994;80(3):535–40. doi:https://doi.org/10.3171/jns.1994.80.3.0535.
- Sandmair A-M, Turunen M, Tyynelä K, Loimas S, Vainio P, Vanninen R, et al. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther. 2000;7(3):413–421. doi:https://doi.org/10.1038/sj.cgt.7700132.
- Robe PA, Nguyen-Khac M, Jolois O, Rogister B, Merville M-P, Bours V. Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells . BMC Cancer. 2005;5:32. doi:https://doi.org/10.1186/1471-2407-5-32.
- Kruse CA, Lamb C, Hogan S, Smiley WR, Kleinschmidt-Demasters BK, Burrows FJ. Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther. 2000;7(1):118–127. doi:https://doi.org/10.1038/sj.cgt.7700097.
- Määttä AM, Liimatainen T, Wahlfors T, Wirth T, Vähä-Koskela M, Jansson L, et al. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer. 2007;121(4):863–70. doi: https://doi.org/10.1002/ijc.22758
- Kruse CA, Visonneau S, Kleinschmidt-DeMasters BK, Gup CJ, Gomez GG, Paul DB, et al. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. Comp. Study (2000). 60(20):5731–9.
- Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, et al. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Mol Ther. 2018;26(1):31–44. doi: https://doi.org/10.1016/j.ymthe.2017.10.002
- Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018;565(7738):234–239.
- Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, et al. The In Vivo Therapeutic efficacy of the oncolytic adenovirus delta24-RGD is mediated by tumor-specific immunity. PLoS One. 2014;9(5):e97495. doi:https://doi.org/10.1371/journal.pone.0097495.
- Xia M, Gasser J, Feige U. Dexamethasone enhances CTLA-4 expression during T cell activation. Cell Mol Life Sci. 1999;55(12):1649–1656. doi:https://doi.org/10.1007/s000180050403.
- Giles AJ, Hutchinson M-KND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51. doi:https://doi.org/10.1186/s40425-018-0371-5.
- Han J, Alvarez-Breckenridge CA, Wang Q-E, Yu J. TGF-β signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5(3):945–955.
- Ständer M, Naumann U, Dumitrescu L, Heneka M, Löschmann P, Gulbins E, et al. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 1998;5(9):1187–1194. doi:https://doi.org/10.1038/sj.gt.3300709.
- Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. Journal of Immunology. 1992;148:277–284.
- Zhou M, Wiemels JL, Bracci PM, Wrensch MR, McCoy LS, Rice T, et al. Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma. Cancer Res. 2010;70(19):7534–7542. doi:https://doi.org/10.1158/0008-5472.CAN-10-0815.
- Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, et al. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology. 2002;143(10):3866–3874. doi:https://doi.org/10.1210/en.2002-220188.
- Rieger J, Ständer M, Löschmann PA, Heneka M, Dichgans J, Klockgether T, et al. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer. Oncogene. 1998;17(18):2323–2332. doi:https://doi.org/10.1038/sj.onc.1202154.
- Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, et al. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1998;78(2):233–9. doi: https://doi.org/10.1038/bjc.1998.470.
- Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. PubMed – NCBI. [cited 2019 Jan 13]. https://www.ncbi.nlm.nih.gov/pubmed/2497225?dopt=Abstract.
- Shinoda J, McLaughlin KE, Bell HS, Swaroop GR, Yamaguchi SI, Holmes MC, et al. Molecular mechanisms underlying dexamethasone inhibition of iNOS expression and activity in C6 glioma cells. Glia 2003;42(1):68–76. doi:https://doi.org/10.1002/glia.10200.
- Hong TM, Teng LJ, Shun CT, Peng MC, Tsai JC. Induced interleukin-8 expression in gliomas by tumor-associated macrophages.J Neurooncol 2009;93(3):289–301. doi:https://doi.org/10.1007/s11060-008-9786-z.
- Klegeris A, Walker DG, McGeer PL. Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J Neuroimmunol 1997;78(1–2):152–61. doi: https://doi.org/10.1016/s0165-5728(97)00094-5.
- Nishida T, Nakai S, Kawakami T, Aihara K, Nishino N, Hirai Y. Dexamethasone regulation of the expression of cytokine mRNAs induced by interleukin-1 in the astrocytoma cell line U373MG. FEBS Lett. 1989;243(1):25–9. doi:https://doi.org/10.1016/0014-5793(89)81210-4.
- Curran CS, Evans MD, Bertics PJ. GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J Immunol. 2011;187(3):1254–63. doi:https://doi.org/10.4049/jimmunol.1001965.
- Kimberlin DW, Willis SA, McCracken GH, Jr, Nisen PD. Protein synthesis-dependent induction of interleukin-1 beta by lipopolysaccharide is inhibited by dexamethasone via mRNA destabilization in human astroglial cells. J Clin Immunol. 1995;15(4):199–204. doi:https://doi.org/10.1007/BF01541090.
- Chang CY, Lee YH, Leu SJ, Wang CY, Wei CP, Hung KS, et al. CC-chemokine ligand 18/pulmonary activation-regulated chemokine expression in the CNS with special reference to traumatic brain injuries and neoplastic disorders. Neuroscience. 2010;165(4):1233–43. doi:https://doi.org/10.1016/j.neuroscience.2009.11.050.
- Fries G, Perneczky A, Kempski O. Enhanced interleukin-1 beta release and longevity of glioma-associated peripheral blood monocytes in vitro. Neurosurgery. 1994;35(2):264–70. doi:https://doi.org/10.1227/00006123-199408000-00012.
- Boker DK, Kalff R, Gullotta F, Weekes-Seifert S, Mohrer U. Mononuclear infiltrates in human intracranial tumors as a prognostic factor. Influence of preoperative steroid treatment. I. Glioblastoma. Clin Neuropathol. 1984;3(4):143–7. https://pubmed.ncbi.nlm.nih.gov/6478676/.
- Galban CJ, Bhojani MS, Lee KC, Meyer CR, Van Dort ME, Kuszpit KK, et al. Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res. 2010;16(5):1542–52. doi:https://doi.org/10.1158/1078-0432.CCR-08-1812.
- Won EK, Zahner MC, Grant EA, Gore P, Chicoine MR. Analysis of the antitumoral mechanisms of lipopolyssacccharide against glioblastoma multiforme. Anticancer Drugs. 2003;14(6):457–66. doi:https://doi.org/10.1097/00001813-200307000-00012.
- Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, et al. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia. (1):78–90. 2015; 63 doi:https://doi.org/10.1002/glia.22734.
- Conte D, Huh M, Goodall E, Delorme M, Parks RJ, Picketts DJ. Loss of Atrx sensitizes cells to DNA damaging agents through p53-mediated death pathways. PLOS One. 2012;7(12):e52167 doi:https://doi.org/10.1371/journal.pone.0052167.
- Piette C, Deprez M, Roger T, Noel A, Foidart JM, Munaut C. The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors. J Biol Chem. 2009;284(47):32483–92. doi:https://doi.org/10.1074/jbc.M109.014589.
- Yoshida H, Imaizumi T, Lee SJ, Tanji K, Sakaki H, Matsumiya T, et al. Retinoic acid-inducible gene-I mediates RANTES/CCL5 expression in U373MG human astrocytoma cells stimulated with double-stranded RNA. Neurosci Res. 2007;58(2):199–206. doi:https://doi.org/10.1016/j.neurres.2007.02.017.
- Dan Q, Trinh H, Williams CC, Lloyd C, Wepsic HT, Jeffes EW, et al. Dexamethasone increases the expression of membrane macrophage colony stimulating factor from retrovirally transduced tumor cells expressing macrophage colony stimulating factor. Int Immunopharmacol. 2001;1(4):737–48. doi:https://doi.org/10.1016/S1567-5769(01)00007-8.
- Rieger J, Durka S, Streffer J, Dichgans J, Weller M. Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol. 1999; 365(2–3):301–8. doi:https://doi.org/10.1016/S0014-2999(98)00883-8.
- Falus A, Beres J. A trace element preparation containing zinc increases the production of interleukin-6 in human monocytes and glial cells. Biol Trace Elem Res. 1996;51(3):293–301. doi:https://doi.org/10.1007/BF02784084.
- Gottschall PE, Tatsuno I, Arimura A. Increased sensitivity of glioblastoma cells to interleukin 1 after long-term incubation with dexamethasone. Mol Cell Neurosci. 1992;3(1):49–55. doi:https://doi.org/10.1016/1044-7431(92)90008-P.